Protect Yourself While There’s Still Time …

The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.

4 simple steps to protect your privacy and money before it’s too late.

Sam Barker Biography and Net Worth

Director of Cyclacel Pharmaceuticals

Dr. Barker has served as a director of the Company since September 2014. Dr. Barker has more than 40 years of experience in senior executive positions in the pharmaceutical industry where he played a significant role in the commercialization and success of several important pharmaceuticals including Taxol®, Capoten®, Glucophage® and Pravachol®. In 2001, Dr. Barker co-founded Clearview Projects, Inc., a provider of partnering and transaction services to biopharmaceutical companies, where he worked until September 2010, having served as its President and Chief Executive Officer from 2003 to 2004. Dr. Barker served in a series of leadership positions at Bristol-Myers Squibb Company until his retirement in 1999. His positions at Bristol-Myers Squibb included service as Executive Vice President, Worldwide Franchise Management and Strategy during 1998; President, United States Pharmaceuticals from 1992 to 1998; and President, Bristol-Myers Squibb Intercontinental Commercial Operations from 1989 to 1991. Prior to 1989, Dr. Barker held executive positions in research and development, manufacturing, business development and operations planning at Squibb Pharmaceuticals. Dr. Barker has served as a director of Lexicon Pharmaceuticals, Inc. since 2001 and as Chairman from 2005 to 2012. Dr. Barker also served as a director of Cadence Pharmaceuticals, Inc. from 2006 to 2014 and AtheroGenics, Inc. from 2005 to 2009. Dr. Barker received his B.S. from Henderson State College, his M.S. from the University of Arkansas and his Ph.D. from Purdue University.

What is Sam L. Barker's net worth?: The estimated net worth of Sam L. Barker is at least $60,280.50 as of August 2nd, 2019. Dr. Barker owns 40,187 shares of Cyclacel Pharmaceuticals stock worth more than $60,281 as of April 26th. This net worth estimate does not reflect any other assets that Dr. Barker may own. Learn More about Sam L. Barker's net worth.
How do I contact Sam L. Barker?: The corporate mailing address for Dr. Barker and other Cyclacel Pharmaceuticals executives is 200 CONNELL DRIVE SUITE 1500, BERKELEY HEIGHTS NJ, 07922. Cyclacel Pharmaceuticals can also be reached via phone at (908) 517-7330 and via email at [email protected]. Learn More on Sam L. Barker's contact information.
Has Sam L. Barker been buying or selling shares of Cyclacel Pharmaceuticals?: Sam L. Barker has not been actively trading shares of Cyclacel Pharmaceuticals during the past quarter. Most recently, Sam L. Barker sold 0 shares of the business's stock in a transaction on Tuesday, November 30th. The shares were sold at an average price of $53.55, for a transaction totalling $0.00. Learn More on Sam L. Barker's trading history.
Who are Cyclacel Pharmaceuticals' active insiders?: Cyclacel Pharmaceuticals' insider roster includes Sam Barker (Director), and Spiro Rombotis (CEO). Learn More on Cyclacel Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Cyclacel Pharmaceuticals?: In the last year, Cyclacel Pharmaceuticals insiders bought shares 2 times. They purchased a total of 7,956 shares worth more than $26,334.36. The most recent insider tranaction occured on December, 21st when insider Paul Mcbarron bought 1,886 shares worth more than $6,242.66. Insiders at Cyclacel Pharmaceuticals own 8.5% of the company. Learn More about insider trades at Cyclacel Pharmaceuticals.
Information on this page was last updated on 12/21/2023.

Sam L. Barker Insider Trading History at Cyclacel Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
11/30/2021	Sell	0	$53.55	$0.00
11/20/2014	Buy	206	$45.00	$9,270.00

Sam L. Barker Buying and Selling Activity at Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals Company Overview

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.

Today's Range

Now: $1.50

$1.46

$1.56

50 Day Range

MA: $2.29

$1.58

$2.97

2 Week Range

Now: $1.50

$1.41

$13.20

Volume

181,588 shs

Average Volume

176,580 shs

Market Capitalization

$1.98 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.54